

APPENDIX

CONTENTS

1. OIG_017183-017186: “lab production analysis” thread with emails dated April 15, 2013; April 17, 2013; April 18, 2013; and April 22, 2013
2. OIG_017165-017170: “lab production analysis” thread with emails dated April 15, 2013, and April 23, 2013
3. OIG_011716-011717: “lab production analysis” thread with emails dated April 15, 2013, and February 14, 2014

OIG_017183-017186: “lab production analysis” thread with emails dated April 15, 2013; April 17, 2013; April 18, 2013; and April 22, 2013

From: "Mark, Audrey C. (IGO)" [REDACTED]
Sent: 4/22/2013 2:27:23 PM -0400
To: "Rudewicz, Frank" [REDACTED]
Subject: RE: Lab production analysis

Sorry if I never responded.

That sounds good to e-mail Mike's work.

Thanks.

--Audrey

Audrey C. Mark
Interim General Counsel
Office of the Inspector General
One Ashburton Place, Room 1311
Boston, MA 02108
Office: 617-722-8852
[REDACTED]

Please note that my new email address is: [REDACTED]

NOTICE: This e-mail message and all attachments transmitted with it may contain legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately by electronic mail and delete this message and all copies and backups thereof. Thank you.

-----Original Message-----

From: Rudewicz, Frank [mailto:[REDACTED]]
Sent: Thursday, April 18, 2013 4:59 AM
To: Mark, Audrey C. (IGO)
Subject: Re: Lab production analysis

Audrey, we've created 2 email group lists from the training , one with Navigant people and one without. I was going to forward Mike's work to the OIG group, okay?

Sent from my iPad

On Apr 17, 2013, at 8:54 PM, "Mark, Audrey (IGO)" [REDACTED] wrote:

> Hi all--

>
> Sorry for the delay. I am out of the office this week...it was supposed to be for a fun vacation with the kids, but has turned into a time at home with one of my kids with a broken arm. Ah, well.
>
> Your analysis is really interesting, Mike. I am looking forward to reviewing it more closely. Thanks so much for the hard work.
>
> --Audrey
>
> From: Rudewicz, Frank [REDACTED]
> Sent: Monday, April 15, 2013 6:36 PM
> To: [REDACTED]
> Cc: Mark, Audrey C. (IGO); Rudewicz, Frank; [REDACTED]
> Subject: Re: Lab production analysis
>
> Thanks Mike. Great work. It looks great. I will call you when I can
>
> Frank E. Rudewicz,
> Partner in Charge, NE Advisory
> [REDACTED]
> Cell [REDACTED]
>
> Sent from my iPhone
>
> On Apr 15, 2013, at 11:17 PM, [REDACTED]
> [REDACTED] wrote:
>
> Audrey, as we discussed last Tuesday, attached is a comparison chart regarding ASD with respect to the overall lab from 2004 - 2011. The focus was on the total samples tested, total heroin and cocaine samples tested (combined for each chemist monthly/annually), total samples that tested negative and the total numbers of other drugs tested. While the total sample numbers and those processed by ASD varied considerably from those provided to us by DPH (Index Tab #53 in their report), the percentages of the cases processed by ASD only varied slightly.
>
> Further comparing ASD's case production with other chemists from the data provided from 2004 - 2011, revealed that several chemists were found to be on par with ASD or exceeding her productivity during extended periods in that time frame. Some of the data was missing for the first 1/2 of 2008, and the 2nd 1/2 of 2011 was not included following the breach on 6/14/11.
>
> From Jan - July 2004 (7 months): ASD tested 1727 cocaine and heroin samples and a total of 4753 samples overall. During that same time period, Sonja Farak tested 2053 cocaine and heroin samples and 4522 total samples.
> From Feb - Dec 2007 (11 months), ASD tested 1524 cocaine and heroin samples and 4216 samples overall. During that same timeframe Kate Corbett (KAC) tested 2134 cocaine and heroin samples and 3127 samples total. ASD tested more "other" drug samples than KAC during that timeframe.
> From July - Dec 2008 (6 months), ASD tested 251 cocaine and heroin samples and 1578 samples overall, as compared to Lisa Glazer (LAG) who tested 801 cocaine and heroin samples and 1634 samples overall. Kate Corbett tested 979 cocaine and heroin samples and 1168 total samples during that same time period.

> From May - Dec (8 months) ASD tested 1235 cocaine and heroin samples and 2368 overall samples, as compared to 1201 cocaine and heroin samples tested by Stacey Desjardins (SLD) and 2863 samples total.

>
>

> In summary, Farak, Corbett, Glazer and Desjardins each neared or exceeded ASD's cocaine/heroin and/or sample testing totals during certain multi-month time periods over the 8 year span. Daniela Frasca (DXF), James Hanchett (JH) and Nicole Medina (NEM) also had high production over shorter timeframes. ASD's consistently high level of sample testing was cited as a "red flag" for management that she was not adhering to testing protocols and SOPS. ASD acknowledged to only testing a portion of her cocaine and heroin samples and "dry labbing" the remainder, which enabled her high production #s. It is recommended that whatever process is developed to review ASD's cases to determine, if possible, which cases were not appropriately tested, also be applied to the other chemists listed above.

>
>

> <Hinton_Lab_stat_analysis.xlsx>

>
>

> CONFIDENTIALITY NOTICE:

> This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of the message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone at (631) 414-4000 or (212) 485-5500 and destroy this message.

>

> IRS CIRCULAR 230 DISCLOSURE NOTICE:

> To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained in this email and/or its attachments, unless otherwise specifically stated, is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code, or (ii) promoting, marketing, or recommending to another party any transaction or matter that is contained in or accompanying this document

CONFIDENTIALITY NOTICE:

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of the message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone at (631) 414-4000 or (212) 485-5500 and destroy this message.

IRS CIRCULAR 230 DISCLOSURE NOTICE:

To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained in this email and/or its attachments , unless otherwise specifically stated, is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code, or (ii) promoting, marketing, or recommending to another party any transaction or matter that is contained in or accompanying this document

OIG_017165-017170: “lab production analysis” thread with emails dated April 15, 2013, and April 23, 2013

From: "Mark, Audrey C. (IGO)" [REDACTED]
Sent: 4/23/2013 9:24:19 AM -0400
To: "Powers, Elizabeth Ann (IGO)" [REDACTED]
Subject: RE: Lab production analysis

General "how are you coming along" meeting

Audrey C. Mark
Interim General Counsel
Office of the Inspector General
One Ashburton Place, Room 1311
Boston, MA 02108
Office: 617-722-8852
[REDACTED]

Please note that my new email address is: [REDACTED]

NOTICE: This e-mail message and all attachments transmitted with it may contain legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately by electronic mail and delete this message and all copies and backups thereof. Thank you.

From: Powers, Elizabeth Ann (IGO)
Sent: Tuesday, April 23, 2013 9:21 AM
To: Mark, Audrey C. (IGO)
Subject: RE: Lab production analysis

Yes, I will. Are we discussing things regarding the emails? Or is there something specific we are discussing.

From: Mark, Audrey C. (IGO)
Sent: Tuesday, April 23, 2013 9:20 AM
To: Powers, Elizabeth Ann (IGO)
Subject: RE: Lab production analysis

Thanks, Liz. Drink your fluids!

Audrey C. Mark
Interim General Counsel
Office of the Inspector General
One Ashburton Place, Room 1311
Boston, MA 02108
Office: 617-722-8852

[REDACTED]

Please note that my new email address is: [REDACTED]

NOTICE: This e-mail message and all attachments transmitted with it may contain legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately by electronic mail and delete this message and all copies and backups thereof. Thank you.

From: Powers, Elizabeth Ann (IGO)
Sent: Tuesday, April 23, 2013 8:23 AM
To: Mark, Audrey C. (IGO)
Subject: RE: Lab production analysis

Coming along hopefully it will be only a couple of days. I will call in but mute my phone so I don't cough

through it. How are you doing? Don't forget tomorrow you have the meeting with the Chief Justices.

From: Mark, Audrey C. (IGO)
Sent: Tuesday, April 23, 2013 8:20 AM
To: Powers, Elizabeth Ann (IGO)
Subject: Re: Lab production analysis


Theirs is fine with me.

Thanks so much.

How do you feel?

--Audrey

Sent from my iPhone

On Apr 23, 2013, at 8:14 AM, "Powers, Elizabeth Ann (IGO)"  wrote:

Hi Audrey:

Allison from Marcum has already set up a conference call number for everyone. I will call in with that number or do you want to use ours. If yes I will set it up this morning.

Liz

From: Mark, Audrey C. (IGO)
Sent: Tuesday, April 23, 2013 7:40 AM
To: Powers, Elizabeth Ann (IGO)
Subject: Fwd: Lab production analysis

Hi Liz--

Attached to this email are jack Mario's and mike wolf's e-mails.

Thanks so much.

--Audrey

Sent from my iPhone

Begin forwarded message:

From: "Rudewicz, Frank" [REDACTED]
Date: April 15, 2013, 6:36:17 PM EDT
To: [REDACTED]
Cc: "Mark, Audrey C. (IGO)" [REDACTED] "Rudewicz, Frank" [REDACTED]
Subject: Re: Lab production analysis

Thanks Mike. Great work. It looks great. I will call you when I can

Frank E. Rudewicz,

Partner in Charge, NE Advisory

[REDACTED]

Cell [REDACTED]

Sent from my iPhone

On Apr 15, 2013, at 11:17 PM, [REDACTED] wrote:

Audrey, as we discussed last Tuesday, attached is a comparison chart regarding ASD with respect to the overall lab from 2004 - 2011. The focus was on the total samples tested, total heroin and cocaine samples tested (combined for each chemist monthly/annually), total samples that tested negative and the total numbers of other drugs tested. While the total sample numbers and those processed by ASD varied considerably from those provided to us by DPH (Index Tab #53 in their report), the percentages of the cases processed by ASD only varied slightly.

Further comparing ASD's case production with other chemists from the data provided from 2004 - 2011, revealed that several chemists were found to be on par with ASD or exceeding her productivity during extended periods in that time frame. Some of the data was missing for the first 1/2 of 2008, and the 2nd 1/2 of 2011 was not included following the breach on 6/14/11.

From Jan - July 2004 (7 months): ASD tested 1727 cocaine and heroin samples and a total of 4753 samples overall. During that same time period, Sonja Farak tested 2053 cocaine and heroin samples and 4522 total samples.

From Feb - Dec 2007 (11 months), ASD tested 1524 cocaine and heroin samples and 4216 samples overall. During that same timeframe Kate Corbett (KAC) tested 2134 cocaine and heroin samples and 3127 samples total. ASD tested more "other" drug samples than KAC during that timeframe.

From July - Dec 2008 (6 months), ASD tested 251 cocaine and heroin samples and 1578 samples overall, as compared to Lisa Glazer (LAG) who tested 801 cocaine and heroin samples and 1634 samples overall. Kate Corbett tested 979 cocaine and heroin samples and 1168 total samples during that same time period.

From May - Dec (8 months) ASD tested 1235 cocaine and heroin samples and 2368 overall samples, as compared to 1201 cocaine and heroin samples tested by Stacey Desjardins (SLD) and 2863 samples total.

In summary, Farak, Corbett, Glazer and Desjardins each neared or exceeded ASD's cocaine/heroin and/or sample testing totals during certain multi-month time periods over the 8 year span. Daniela Frasca (DXF), James Hanchett (JH) and Nicole Medina (NEM) also had high production over shorter timeframes. ASD's consistently high level of sample testing was cited as a "red flag" for management that she was not adhering to testing protocols and SOPs. ASD acknowledged to only testing a portion of her cocaine and heroin samples and "dry labbing" the remainder, which enabled her high production #s. It is recommended that whatever process is developed to review ASD's cases to determine, if possible, which cases were not appropriately tested, also be applied to the other chemists listed above.

<Hinton_Lab_stat_analysis.xlsx>

CONFIDENTIALITY NOTICE:

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of the message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone at (631) 414-4000 or (212) 485-5500 and destroy this message.

IRS CIRCULAR 230 DISCLOSURE NOTICE:

To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained in this email and/or its attachments , unless

otherwise specifically stated, is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code, or (ii) promoting, marketing, or recommending to another party any transaction or matter that is contained in or accompanying this document

OIG_011716-011717: “lab production analysis” thread with emails dated April 15, 2013, and February 14, 2014

From: [REDACTED]
Sent: 2/12/2014 8:58:57 AM -0500
To: "Powers, Elizabeth Ann (IGO)"
[REDACTED]
Subject: Fwd: Lab production analysis
Attachments: Hinton_Lab_stat_analysis.xlsx

Liz, this isn't important at this time with noon tomorrow looming, but as follow up to our conference call last week when productivity of other chemists relative to ASD came up, I ran across this, this morning. I provided you the attachment awhile back that admittedly is based on DPH records that aren't totally complete or accurate but it certainly puts comparative sample production in perspective, especially regarding Farak, Corbett, Glazer and Desjardins. Nothing pressing but after almost a year of scrutiny is interesting. Hang in there, its almost over. Mike

-----Original Message-----

From: mjwolf50 [REDACTED]
To: audrey.mark [REDACTED] frank.rudewicz [REDACTED]
[REDACTED]; jmario111 [REDACTED]
Sent: Mon, Apr 15, 2013 5:17 pm
Subject: Lab production analysis

Audrey, as we discussed last Tuesday, attached is a comparison chart regarding ASD with respect to the overall lab from 2004 - 2011. The focus was on the total samples tested, total heroin and cocaine samples tested (combined for each chemist monthly/annually), total samples that tested negative and the total numbers of other drugs tested. While the total sample numbers and those processed by ASD varied considerably from those provided to us by DPH (Index Tab #53 in their report), the percentages of the cases processed by ASD only varied slightly.

Further comparing ASD's case production with other chemists from the data provided from 2004 - 2011, revealed that several chemists were found to be on par with ASD or exceeding her productivity during extended periods in that time frame. Some of the data was missing for the first 1/2 of 2008, and the 2nd 1/2 of 2011 was not included following the breach on 6/14/11.

From Jan - July 2004 (7 months): ASD tested 1727 cocaine and heroin samples and a total of 4753 samples overall. During that same time period, Sonja Farak tested 2053 cocaine and heroin samples and 4522 total samples.

From Feb - Dec 2007 (11 months): ASD tested 1524 cocaine and heroin samples and 4216 samples overall. During that same timeframe Kate Corbett (KAC) tested 2134 cocaine and heroin samples and 3127 samples total. ASD tested more "other" drug samples than KAC during that timeframe.

From July - Dec 2008 (6 months): ASD tested 251 cocaine and heroin samples and 1578 samples overall, as compared to Lisa Glazer (LAG) who tested 801 cocaine and heroin samples and 1634 samples overall. Kate Corbett tested 979 cocaine and heroin samples and 1168 total samples during that same time period.

From May - Dec (8 months) ASD tested 1235 cocaine and heroin samples and 2368 overall samples, as compared to 1201 cocaine and heroin samples tested by Stacey Desjardins (SLD) and 2863 samples total.

In summary, Farak, Corbett, Glazer and Desjardins each neared or exceeded ASD's cocaine/heroin and/or sample testing totals during certain multi-month time periods over the 8 year span. Daniela Frasca (DXF), James Hanchett (JH) and Nicole Medina (NEM) also had high production over shorter timeframes. ASD's consistently high level of sample testing was cited as a "red flag" for management that she was not adhering to testing protocols and SOPS. ASD acknowledged to only testing a portion of her cocaine and heroin samples and "dry labbing" the

remainder, which enabled her high production #s. It is recommended that whatever process is developed to review ASD's cases to determine, if possible, which cases were not appropriately tested, also be applied to the other chemists listed above.